MedTrace Logo

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

NCT03930680 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.

Conditions

  • Degradation of Top2b and Top2a in Human by Dexrazoxane
  • Time Course and Degradation of Top2b in Human by Dexrazoxane
  • Effects of Dexrazoxane on Healthy Human

Interventions

DRUG

Dexrazoxane

One dose of dexrazoxane

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Hui-Ming Chang, MD,MPH · University of Arkansas

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2024-06-11
Completion
2025-06-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03930680 on ClinicalTrials.gov